Curium wraps up patient enrollment in ECLIPSE trial in prostate cancer
Curium, a leading figure in the global nuclear medicine sector, has proudly announced the successful completion of patient enrollment in the pivotal Phase 3 ECLIPSE ... Read More
Novartis gets Pluvicto EC approval for advanced prostate cancer
Novartis has received the approval of the European Commission (EC) for Pluvicto (lutetium (177Lu) vipivotide tetraxetan), a targeted radioligand therapy for advanced prostate cancer. Following ... Read More
Clinical-stage pharma firms Ayala Pharmaceuticals, Advaxis sign merger deal
Ayala Pharmaceuticals, a Nasdaq-listed clinical-stage oncology company, has entered into a merger deal with New Jersey-based biotech company Advaxis. Based in Delaware, Ayala Pharmaceuticals is ... Read More
Merck signs $290m deal with Orion Corporation for mCRPC candidate ODM-208
Merck has signed a global development and commercialization deal worth $290 million with Orion Corporation for the latter’s investigational candidate ODM-208 and other drugs that ... Read More
Liquid biopsy company ANGLE plc bags pharma services contract
UK-based liquid biopsy company ANGLE plc has won a pharma services contract worth up to $1.2 million from an undisclosed pharma company that is engaged ... Read More
Cancer Targeted Technology gets NIH grant to support CTT1403 trial
Cancer Targeted Technology (CTT), a Seattle-based biotech company, has secured a grant of $1.44 million from the US National Institutes of Health (NIH) to support ... Read More
GSK completes $5.1bn acquisition of Tesaro to boost oncology pipeline
GlaxoSmithKline (GSK), the British pharmaceutical powerhouse, has successfully concluded its $5.1 billion acquisition of Tesaro, a leading oncology-focused biopharmaceutical company based in Waltham, Massachusetts. This ... Read More
Novartis completes $2.1bn acquisition of Endocyte to boost cancer treatment capabilities
Swiss pharmaceutical giant Novartis has officially closed its $2.1 billion acquisition of US-based biopharma company Endocyte, solidifying its position as a leader in radiopharmaceuticals for ... Read More
US biopharma company Endocyte to be acquired by Novartis for $2.1bn
Novartis acquisition of Endocyte : US biopharma company Endocyte has agreed to be acquired by Swiss pharma company Novartis in a deal worth around $2.1 ... Read More
Novartis to expand radiopharmaceuticals portfolio with $2.1bn Endocyte acquisition
Swiss pharmaceutical company Novartis has announced a strategic acquisition of the US-based biopharma firm Endocyte for approximately $2.1 billion. This move aims to bolster Novartis’s ... Read More